Clinical Trials Logo

Clinical Trial Summary

This phase II trial tests whether cabozantinib and atezolizumab work to shrink tumors in patients with castrate-resistant prostate cancer that had spread to other places in the body (metastatic). Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib and atezolizumab may kill more tumor cells in patients with metastatic castrate-resistant prostate cancer.


Clinical Trial Description

PRIMARY OBJECTIVE: I. To evaluate the disease control rate in metastatic castration-resistant prostate cancer (mCRPC) patients with non-measurable disease as assessed by Prostate Cancer Working Group 3 (PCWG3)-modified Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 SECONDARY OBJECTIVES: I. To evaluate the efficacy of the combination as measured by prostate-specific antigen (PSA) progression-free survival (PFS). II. To evaluate the efficacy of the combination as measured by PSA 50% response rate. III. To evaluate the efficacy of the combination as measured by radiographic progression-free survival (PFS). IV. To evaluate the efficacy of the combination as measured by overall survival (OS). V. To evaluate the safety of cabozantinib S-malate (cabozantinib) in combination with atezolizumab in patients with mCRPC with non-measurable disease. EXPLORATORY OBJECTIVE: I. To analyze tissue and tumor-based biomarkers to evaluate the mechanisms of treatment activity and resistance. OUTLINE: Patients receive cabozantinib orally (PO) once daily (QD) on days 1-21 and atezolizumab intravenously (IV) over 30-60 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 30 days and then every 3 months until disease progression or start of another therapy. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05168618
Study type Interventional
Source University of Utah
Contact Susan Sharry
Phone 801-585-3453
Email susan.sharry@hci.utah.edu
Status Recruiting
Phase Phase 2
Start date March 11, 2022
Completion date January 2027

See also
  Status Clinical Trial Phase
Active, not recruiting NCT04716725 - 68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer Phase 2
Active, not recruiting NCT03218826 - PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery Phase 1
Active, not recruiting NCT04033432 - sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Phase 2
Completed NCT01881867 - CYT107 After Vaccine Treatment (Provenge®) in Patients With Metastatic Castration-Resistant Prostate Cancer Phase 2
Not yet recruiting NCT06236139 - Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer Phase 1/Phase 2
Recruiting NCT04071236 - Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy Phase 1/Phase 2
Active, not recruiting NCT02522715 - Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Phase 1/Phase 2
Terminated NCT04951492 - Olaparib for the Treatment of Castration Resistant Prostate Adenocarcinoma Phase 2
Active, not recruiting NCT04514484 - Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV Phase 1
Active, not recruiting NCT03344211 - Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer Phase 2
Active, not recruiting NCT02312557 - Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide Phase 2
Recruiting NCT04159896 - ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer Phase 2
Completed NCT05547386 - 68Ga-PSMA-11 PET/CT Screening Prior to 177Lu-PSMA-617 Therapy for Patients With Metastatic Castrate Resistant Prostate Cancer Phase 3
Recruiting NCT05960578 - Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study Phase 2
Recruiting NCT06200103 - Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer Phase 2
Active, not recruiting NCT03517969 - M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Phase 2
Recruiting NCT06039371 - Supraphysiological Androgen to Enhance Chemotherapy Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study Phase 2
Active, not recruiting NCT02703623 - Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Phase 2
Recruiting NCT04777071 - An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer Phase 2
Active, not recruiting NCT03805594 - 177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Phase 1